A Pilot Study of the Effects of Vivostat Patient-derived Fibrin Sealant in Reducing Blood Loss in Primary Hip Arthroplasty

Abstract

A pilot study evaluated the effectiveness of Vivostat patient-derived fibrin sealant in reducing blood loss in patients who underwent primary hip arthroplasty. Eighty adult patients undergoing elective surgery were randomized to receive either Vivostat sealant or control (no additional hemostatic treatment). Patients allocated Vivostat sealant donated 120 mL of blood, which was then processed perioperatively to produce a fibrin sealant that was applied to the bleeding wound surfaces just before closure. Transfusion requirements, blood loss during surgery, drain volumes, and daily hematocrit and hemoglobin levels were measured. Hospitalization times, adverse events, and postoperative wound complications were also monitored. Blood loss during surgery and wound drainage volume was lower in the Vivostat group than in the control group, although the differences were not significantly different. Transfusion requirements (median, 270 mL of packed red blood cells) and hospitalization times (both median 7 days) were the same for both groups. No adverse events related to the use of Vivostat occurred. There were indications of a possible reduction in the incidence of postoperative wound oozing (15% vs 25%) and hematomas (6% vs 11%) with the use of Vivostat compared with the control group, although differences were not statistically significant. In conclusion, in this pilot study, use of Vivostat patient-derived fibrin in hip arthroplasty was not associated with a significant reduction in blood loss. Further studies, with larger numbers of patients, may be warranted to investigate a possible benefit of Vivostat in reducing postoperative wound complications.

Keywords

Fibrin sealant Arthroplasty Hip surgery Surgical blood loss Randomized clinical trial

References

Hepinstall MS , Colwell CW Jr , Macaulay WB . Blood conservation in primary total hip arthroplasty. J South Orthop Assoc 2003;12:95-95.

Carless PA , Henry DA , Anthony DM . Fibrin sealant use for minimising perioperative allogeneic blood transfusion (Cochrane Review). In: The Cochrane Library. Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2004.

Levy O , Martinowitz U , Oran A , et al. The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am 1999;81:1580-1580.

Wang GJ , Hungerford DS , Savory CG , et al. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg Am 2001;83A:1503-1503.

Kjaergard HK , Fairbrother JE , Cederholm-Williams SA , et al. The Vivostat System for the automated preparation of autologous fibrin sealant. Cardiovasc Eng 1997;2:204-204.

Dodd RA , Cornwell R , Holm NE , et al. The Vivostat application system: A comparison with conventional fibrin sealant application systems. Technol Health Care 2002;10:401-401.

Hanks JB , Kjaergard HK , Hollingsbee DA . A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res 2003;35:439-439.

Drake DB , Wong LG . The hemostatic effect of Vivostat patient-derived fibrin sealant on split-thickness skin graft donor sites. Ann Plast Surg 2003;50:367-367.

Kjaergard HK , Trumbull HR . Bleeding from the sternal marrow can be stopped using Vivostat patient-derived fibrin sealant. Ann Thorac Surg 2002;69:1173-1173.

10.

Saleh K , Olson M , Resig S , Bershadsky B , et al. Predictors of wound infection in hip and knee joint replacement: Results from a 20 year surveillance program. J Orthop Res 2002;20:506-506.